ASCO 2023 – Novocure sinks as Lunar’s limitations become clear

[cafead]

via Confidence in Novocure’s ability to break into lung cancer with its tumour-treating fields technology took a major knock yesterday, as doctors at Asco raised serious questions about the therapy’s value as a second-line treatment. Shares in the company plunged 43%.

article source